The legendary Def Jam graphic artist who created the cover of Biggie Small’s “Ready to Die” has been reimagining the Mets’ ...
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current ...
Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.
As previously reported, Guggenheim initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $31 price target. There remains a ...
Zacks Investment Research on MSN1d
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to NoteIn the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.
A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
Google’s $32B Wiz acquisition raises questions on strategy, AI competition, and cloud dominance as investors react ...
Zacks Investment Research on MSN5d
GILD Stock Down on Report of Cut in HIV Prevention SpendingShares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...
Alisa Melekhina, a litigation partner at Kirkland, offers best practice advice for making the most of your litigation data set and provides ideas to assist in leveraging litigation review workflows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback